What MOTs-c is, exactly
MOTs-c stands for “Mitochondrial Open Reading frame of the Twelve S rRNA-c.” It is a 16-amino-acid peptide. That is short, even by peptide standards: most signaling peptides discussed in clinical contexts run from roughly 15 to 50 residues, and many therapeutic peptides on the market are considerably longer. MOTs-c sits firmly at the small end.
The detail that makes MOTs-c biologically distinctive is not its length but its location in the genome. Its coding sequence sits inside the 12S ribosomal RNA gene of human mitochondrial DNA. Specifically, MOTs-c is encoded by a small open reading frame nested within the 12S rRNA gene, which was historically considered to be a non-coding region whose only job was to produce one of the structural RNAs that mitochondrial ribosomes need in order to translate other mitochondrial proteins.
For decades, the standard textbook framing was that mitochondrial DNA encodes 13 proteins (all components of the electron transport chain), 22 tRNAs, and 2 rRNAs. The discovery that there are functional small open reading frames embedded within the rRNA genes themselves, producing peptides with biological activity, expanded that picture. MOTs-c is the most studied example.
The peptide is small, conserved across mammals, and detectable in human plasma and skeletal muscle. It is one of a handful of mitochondrial-derived peptides that researchers have characterized, alongside humanin and the small humanin-like peptide (SHLP) family. Together this group is referred to as the MDP class, and MOTs-c is widely treated as the prototypical member.
Why mitochondrial encoding matters
It is reasonable to ask whether the genome of origin is a biological detail that matters or a piece of trivia. For MOTs-c, it matters in three concrete ways.
Different evolutionary lineage
Mitochondrial DNA has its own evolutionary history, distinct from the nuclear genome. It is inherited through the maternal line, replicates on its own schedule, and accumulates mutations at a different rate than nuclear DNA. A peptide encoded in mitochondrial DNA is part of a regulatory system that has been shaped by mitochondrial-specific evolutionary pressures, which is not the case for the vast majority of peptide hormones.
A retrograde signaling axis
A peptide produced inside the mitochondrion is positioned to act as a retrograde signal, that is, a way for the mitochondrion to communicate its metabolic state back to the rest of the cell, including the nuclear genome. Cells routinely send signals from nucleus to mitochondria. Sending signals in the opposite direction, from mitochondria back to the nucleus, is less well characterized. MOTs-c gives this concept a concrete molecular candidate.
Implications for biology and disease
Mitochondrial dysfunction is implicated in aging, metabolic disease, neurodegeneration, and a range of inherited mitochondrial disorders. The possibility that the mitochondrion produces its own peptide hormones, which may decline or shift with mitochondrial stress, gives researchers a new lens through which to study these conditions. This is part of why MOTs-c, despite a modest absolute number of human studies, has attracted disproportionate attention in metabolism and aging research.
The discovery: how the Cohen and Lee group at USC found MOTs-c
MOTs-c was identified and characterized by a research group led by Dr. Pinchas Cohen and Dr. Changhan Lee at the University of Southern California. The defining publication is Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P, “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance,” published in Cell Metabolism in 2015 (volume 21, issue 3, pages 443 to 454).
The methodological backstory is worth understanding. The Cohen group had already been working on humanin, a different small peptide whose coding sequence is also embedded in the mitochondrial genome (in the 16S rRNA gene). Humanin had been described in the early 2000s in the context of cellular stress and neuroprotection. That work raised an obvious question: if there is a functional small open reading frame inside the 16S rRNA gene, are there others elsewhere in mitochondrial DNA?
The team applied a systematic computational and biochemical search to mitochondrial DNA, looking for small open reading frames that had the hallmarks of producing biologically active peptides. MOTs-c emerged from that screen. The 2015 paper combined the computational identification with wet-lab confirmation: synthesizing the peptide, validating that the predicted sequence was produced and detectable in tissue, and then asking what it did when administered to mice.
The biological findings in that first paper, which we will discuss in more detail in the mechanism section, were striking enough to launch the broader MDP field. They also raised follow-up questions that the field is still working through more than a decade later.
The broader MDP field MOTs-c launched
MOTs-c is the most-cited member of an emerging peptide class called mitochondrial-derived peptides. The class has a few defining features that distinguish it from other peptide hormone families.
- Mitochondrial encoding. All members of the class are translated from open reading frames within mitochondrial DNA, not nuclear DNA. This is the defining structural criterion.
- Small size. MDPs identified to date are short, generally 16 to 24 amino acids, which constrains their binding modes and pharmacokinetics.
- Stress-responsive expression. Across the family, expression is modulated by mitochondrial state, metabolic stress, exercise, fasting, and aging.
- Cross-tissue effects. MDPs appear in plasma and act on tissues distant from their site of production, consistent with hormone-like behavior.
In addition to MOTs-c and humanin, the SHLP family (small humanin-like peptides, designated SHLP1 through SHLP6) has been characterized by the same research community. None of these peptides have approved therapeutic applications. They are research tools and biological signals, and their clinical translation is still in early stages.
Proposed mechanism: AMPK, the folate cycle, and the “exercise mimetic” framing
The mechanistic picture for MOTs-c, as developed by the Cohen and Lee group and subsequent collaborators, centers on a small set of pathways that show up repeatedly in metabolic biology.
AMPK activation
AMP-activated protein kinase, or AMPK, is the cell’s central energy sensor. When the AMP-to-ATP ratio rises (a sign that the cell is running low on energy), AMPK turns on and promotes processes that generate ATP, such as glucose uptake and fatty acid oxidation, while inhibiting processes that consume ATP, such as protein synthesis through mTOR. The 2015 Lee paper and follow-on work indicate that MOTs-c administration activates AMPK in skeletal muscle, which is the same pathway engaged by metformin and by the metabolic stress of physical activity.
Folate and methionine cycle modulation
The original paper described a particular biochemical link between MOTs-c and the folate cycle, with knock-on effects on methionine metabolism and on the cellular AICAR pool. AICAR is an AMPK activator in its own right, which provides a plausible biochemical bridge between MOTs-c and AMPK activation. The folate cycle connection also suggests interactions with one-carbon metabolism, a network that connects nutrient state to DNA methylation, amino-acid synthesis, and redox balance.
Insulin sensitivity and glucose handling
In high-fat-diet mouse models, MOTs-c administration was associated with preserved insulin sensitivity, improved glucose tolerance, and reduced fat accumulation. The mechanism is consistent with AMPK-driven GLUT4 (the insulin-responsive glucose transporter) translocation in skeletal muscle, a pathway that increases glucose disposal independent of insulin in the same way that exercise does.
Fatty acid oxidation
AMPK activation also shifts substrate use toward fatty acid oxidation in skeletal muscle. Preclinical MOTs-c work is consistent with this signature, which contributes to the metabolic profile observed in the high-fat-diet mouse studies.
The “exercise mimetic” framing
Because the pathway profile of MOTs-c (AMPK activation, increased GLUT4 translocation, increased fatty acid oxidation) overlaps significantly with the cellular signature of physical activity, MOTs-c is sometimes described as an exercise mimetic in popular accounts. The label is shorthand and it deserves caveats: a single peptide engaging a few overlapping pathways is not equivalent to the systemic adaptation produced by sustained exercise, which involves cardiovascular remodeling, neuromuscular adaptation, hormonal shifts, and tissue-level structural changes that no single molecular agent replicates. The exercise-mimetic framing is a useful conceptual handle, not a literal claim of equivalence.
The state of the evidence
Honest evaluation of MOTs-c requires distinguishing several categories of evidence, because the strength varies considerably across them.
Preclinical mouse data
The preclinical record for MOTs-c, while modest in volume compared to a peptide like BPC-157, is methodologically reasonable. The 2015 Lee paper used standard metabolic phenotyping in mice (glucose tolerance tests, insulin tolerance tests, body composition, energy expenditure) and reported consistent directional findings under high-fat-diet conditions. Follow-up papers from the same group and collaborators have extended the picture into exercise physiology, aging, and tissue-level retrograde signaling.
Human observational data
Human work on MOTs-c is dominated by observational measurement of endogenous circulating MOTs-c, not interventional administration. Plasma MOTs-c declines with chronological age, and acute exercise raises both circulating MOTs-c and MOTs-c expression in human skeletal muscle. These observations are credible and have been replicated, but they characterize the body’s own MOTs-c regulation, not the effect of giving MOTs-c as a drug to a person.
Human interventional data
Large randomized controlled trials of exogenous MOTs-c administration in humans, the kind of study that would establish efficacy and safety for a given indication, have not been published. This is the central evidence gap in the MOTs-c story and it is the gap that any responsible discussion of the peptide has to acknowledge directly.
The CohBar story: a clinical translation attempt
The MOTs-c story is incomplete without CohBar Inc., a USC spinout founded in part by the same researchers who characterized MOTs-c. CohBar was set up specifically to translate mitochondrial-derived peptide biology into pharmaceutical candidates.
In the late 2010s and early 2020s, CohBar advanced MDP-derived analog programs through preclinical work and into early-phase clinical evaluation. The company explored applications in metabolic disease, NASH (non-alcoholic steatohepatitis), and related conditions. Despite the publication base and the credibility of the underlying science, CohBar did not bring a MOTs-c product to market. The company eventually wound down its operations without a commercial launch.
This is informative for several reasons. It demonstrates that experienced pharmaceutical translators with intellectual property, capital, and direct ties to the original research group attempted exactly the path that would produce a regulated MOTs-c therapy and were not able to complete it. The failure to translate is not the same as a failure of the underlying biology, but it does mean that the regulated, clinically validated MOTs-c product that some marketing language implies is not in fact something the field has produced.
US regulatory status: Category 2 history and the April 2026 regulatory ambiguity
MOTs-c has no FDA-approved drug application. It has not been evaluated as a dietary supplement ingredient and would not qualify under DSHEA in any case. Historically, MOTs-c was placed on the FDA’s Category 2 list of bulk drug substances, the category that compounding pharmacies are not permitted to use. As of the FDA’s April 15, 2026 update, MOTs-c is part of the cohort that was removed from the Category 2 list but has not been placed on Category 1, leaving the peptide in a regulatory ambiguity pending review by the Pharmacy Compounding Advisory Committee (PCAC).
Because PepScribe’s pharmacy standard is 503A-only, and because MOTs-c does not have a clear Category 1 designation, MOTs-c is not a peptide-direct product on this platform. It is treated as a consultation-first compound, where a licensed clinician decides whether and how a research peptide fits into a given patient’s plan, within the formulary that is available under current US compounding rules.
The legal status article in this cluster goes deeper into the regulatory picture, including the international view and the comparison to the Tier 1 metabolic peptides that are clinically available today.
Safety: an endogenous peptide is not the same as exogenous dosing
One of the more common misframings of MOTs-c is the “your body already makes it” argument: because MOTs-c is endogenous, the reasoning goes, administering more of it must be safe. This is a reasonable starting heuristic, but it has important limits.
- Dose-response. The body produces MOTs-c in a tightly regulated, context-dependent way that responds to metabolic state. Exogenous bolus dosing imposes a different pharmacokinetic profile and a different concentration over time than endogenous regulation produces.
- Pharmacokinetics. Half-life, tissue distribution, and clearance for exogenously administered MOTs-c in humans have not been well characterized in published controlled trials.
- Drug interactions. AMPK is a central energy-regulating pathway. Sustained pharmacologic engagement of AMPK in patients on insulin, sulfonylureas, metformin, GLP-1 receptor agonists, or thiazolidinediones is a clinical question that warrants prescriber oversight, not self-administration.
- Long-term effects. Long-term human safety data for exogenous MOTs-c does not exist in the published literature. Animal data is reassuring at the doses studied but does not substitute for human longitudinal evidence.
- Population variability. Effects in pregnant or nursing individuals, in patients with established diabetes, in patients with significant cardiovascular disease, or in immunocompromised populations have not been characterized.
None of this means MOTs-c is dangerous. It means the human safety database is small enough that the responsible position is caution, prescriber oversight, and an honest framing of what is and is not known.
Administration in research and gray-market settings
In published preclinical research, MOTs-c is most often administered by injection. In rodent studies, intraperitoneal administration is common, and subcutaneous protocols have also been described. Established human dosing protocols supported by completed pharmacokinetic studies have not been published.
Compounded MOTs-c circulating in the gray-market and in some compounding channels is typically offered as a lyophilized powder for reconstitution and subcutaneous injection. Dosing claims associated with these products are generally extrapolations from animal work, not human evidence-based regimens. Injecting a compounded peptide without prescriber oversight, particularly one that engages a pathway as fundamental as AMPK, is not a substitute for a clinician-supervised plan.
MOTs-c and the longevity peptide zeitgeist
MOTs-c sits at the intersection of three zeitgeisty narratives in current wellness culture: longevity, metabolic optimization, and exercise mimicry. Each of those narratives is genuinely interesting in scientific terms. Each is also a magnet for marketing language that runs ahead of the evidence.
Healthy skepticism in this domain looks like the following: take the mechanistic picture seriously without treating it as proof of clinical efficacy, recognize that an endogenous peptide is a different thing from a pharmaceutical, expect a real therapeutic to require the kind of trial program that CohBar attempted, and route metabolic concerns through the clinically validated tools that already exist before reaching for a research peptide.
For most readers, the practical takeaway is that MOTs-c is best understood as an open and active research target rather than as a treatment to seek out today. If your underlying interest is metabolic health, weight regulation, or insulin sensitivity, the better-supported clinical pathway runs through Tier 1 GLP-1-class therapies such as semaglutide and the dual GIP and GLP-1 agonist tirzepatide, both of which have substantial randomized human trial data and are clinically available through licensed compounding pharmacies under current US rules.